3'-Deoxy-3'-[18F]-fluorothymidine
Phase 1
3'-Deoxy-3'-[18F]-fluorothymidine is one of 18 therapeutic programs targeting Metastatic Castration-Resistant Prostate Cancer. It is currently in Phase 1.
1
Indications
1
Total Trials
1
Active Trials
17
Competitors
Pipeline
Status by Indication[2][1]
Indication
Competition
Competitive Landscape
25 competitors in Metastatic Castration-Resistant Prostate Cancer
#DrugCompanyPhaseTrials
1Xtandi
AstellasApproved
Zytiga
Johnson & JohnsonPhase 3
Nubeqa
BayerPhase 3
Lynparza
AstraZenecaPhase 3
Taxotere
AAvyxa
Phase 3
Keytruda
Merck & Co.Phase 2
Velcade
SShilpa Grover, MD, MPH
Phase 2
XL092
RochePhase 2
Zanzalintinib
Merck & Co.Phase 2
Cabometyx
Bristol-Myers SquibbPhase 1
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Timeline
Expected Milestones
Clinical
Trials by Indication[1]
Sources
References
- [1]
- [2]
- [3]
Details
Drug Info
Quick Facts
- Highest Phase
- Phase 1[1]
- Company
- UUniversity of Wisconsin, Madison